ACIP recommends:
"All children should receive hepatitis A vaccine at age 1 year (ie, 12–23 months)"¹

Hepatitis A can result in serious consequences²

• In 2004, 1 out of every 5 reported cases of hepatitis A in children under 15 years of age required hospitalization²
• Sudden outbreaks can occur
  1

Help protect children from hepatitis A with HAVRIX

HAVRIX is indicated for active immunization of persons >12 months of age against disease caused by hepatitis A virus (HAV).

• HAVRIX is administered as a 2-dose series with the initial dose followed by a booster dose 6 to 12 months later

Important Safety Information
In clinical trials, the most common solicited adverse events were injection-site soreness and headache. Greater incidences of general adverse events were observed in subjects who received HAVRIX at the same time as Hib conjugate and DTaP vaccines. As with any vaccine, rare adverse events may occur. (See Adverse Reactions section of the Prescribing Information for HAVRIX for potential side effects.) HAVRIX is contraindicated in people with hypersensitivity to any component of the vaccine, including neomycin.

Click here for complete Prescribing Information

References: 1. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR. 2006;55(RR-7):1-23. 2. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 61. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services.
Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967.